Bayer Boston Consulting Group Matrix
Unlock Strategic Clarity
Bayer’s BCG Matrix preview highlights how its diverse portfolio—pharmaceuticals, crop science, and consumer health—align across Stars, Cash Cows, Question Marks, and Dogs, revealing where growth potential and cash generation intersect with strategic risk. This snapshot shows which divisions drive market share and which may need divestment or reinvention. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Nubeqa Prostate Cancer Treatment
Nubeqa (darolutamide) reached blockbuster status with global sales above 1.5 billion euros by end-2025, growing >75% year-on-year and driving Pharmaceuticals segment revenue growth.
It’s rapidly gaining share as a leading androgen receptor inhibitor for metastatic hormone-sensitive prostate cancer and is a primary growth engine for Bayer.
A third regulatory approval in China is expected in 2026; Bayer is investing heavily in promotion to cement Nubeqa as a standard of care.
Kerendia for Chronic Kidney Disease
Kerendia for Chronic Kidney Disease is a Stars asset: sales surged nearly 87% in 2025 to about EUR 1.1 billion, driven by clear impact in type 2 diabetes patients with kidney disease.
The product is expanding via new indications, including 2025 priority reviews for heart failure, widening addressable market to ~45 million high-risk patients globally.
By end-2025 Kerendia plus Nubeqa formed Bayer’s pharma recovery backbone, contributing roughly EUR 2.3 billion combined sales; continued investment is needed to fend off renal and CV competitors.
Dekalb Hybrid Corn Portfolio
Dekalb Hybrid Corn is a Star in Bayer’s BCG matrix, holding a dominant 28% market share in India as of Q4 2025 and delivering double-digit revenue growth with ~22% ROI.
Bayer invested heavily in FY 2024–25 to expand global seed processing capacity, raising capex by about €300 million to meet rising demand for high-yield hybrids.
Projected to become a major cash generator for Crop Science, Dekalb’s high growth and strong margins support scaling R&D and global commercialization through 2026.
Eylea 8mg High-Dose
Eylea 8mg High-Dose has defended Bayer’s ophthalmology share by cutting dosing frequency, helping patient retention and adherence.
It showed mid-single-digit global sales growth in 2025, cushioning Bayer from biosimilar pressure on the 2mg dose.
Leading in the growing AMD and diabetic retinopathy markets, it stays a high-value Star backed by strategic marketing and robust clinical data.
- 2025 growth: ~5–7% global sales rise
- Fewer injections: extends dosing to Q12 weeks
- Offsets 2mg biosimilars
- High margin specialty product
Elinzanetant Menopause Management
Elinzanetant Menopause Management launched in late 2025 in the USA and Europe as a first-in-class non-hormonal therapy for vasomotor symptoms, entering a high-growth menopause market forecasted at ~6–8 billion euros by 2028; analysts project peak sales for Elinzanetant to exceed 1 billion euros.
As a first-to-market innovative product, it needs heavy Bayer support for market access and physician education—estimated launch investment €200–€350M—and, if current uptake holds, is on track to become the Women’s Healthcare segment’s primary revenue driver by 2027.
- Launch: late 2025 (US, EU)
- Type: non-hormonal, first-in-class
- Market size: ~€6–8B by 2028
- Peak sales: >€1B (analyst consensus)
- Estimated launch spend: €200–€350M
- Key year: primary driver by 2027
Bayer’s Blockbusters Surge: Nubeqa €1.5B, Kerendia €1.1B, Elinzanetant >€1B
Bayer Stars: Nubeqa €1.5B (2025), +75% YoY; Kerendia €1.1B, +87% (2025); Dekalb corn 28% India share, ~22% ROI; Eylea 8mg +5–7% (2025); Elinzanetant launch late‑2025, peak >€1B.
| Product | 2025 sales/metric | Growth/notes |
|---|---|---|
| Nubeqa | €1.5B | +75% YoY |
| Kerendia | €1.1B | +87% YoY |
| Dekalb | 28% India | ~22% ROI |
| Eylea 8mg | mid‑single % | Q12 dosing |
| Elinzanetant | launch 2025 | peak >€1B |
What is included in the product
Detailed Word Document
In-depth BCG review of Bayer’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page Bayer BCG Matrix placing each business unit in a quadrant for swift portfolio decisions
Cash Cows
Xarelto Anticoagulant Portfolio
Despite patent expirations and a 31% sales drop in Q1 2025, Xarelto (rivaroxaban) remains a major cash generator for Bayer, still delivering estimated annual net sales around €3.4 billion in 2024 and funding operations into 2025.
It holds a leading share in the mature anticoagulation market, requires minimal new capex, and its high cash conversion funds R&D for new launches and supports debt service—Bayer reported net debt of €18.9 billion at end-2024.
As the quintessential Cash Cow in Bayer’s BCG matrix, Xarelto provides the liquidity backbone for the company’s turnaround strategy while management milks remaining revenues to preserve margin and free cash flow.
Mirena Contraceptive Family
The Mirena contraceptive family, including Kyleena and Jaydess, stays the market leader in the mature long-acting reversible contraceptive (LARC) segment; in 2025 combined sales grew over 20% year-on-year to roughly €2.6 billion, driven by strong brand loyalty and high gross margins near 80%.
Arize Hybrid Rice
Arize Hybrid Rice holds a 32% share of the organized hybrid rice market in Asia and contributes about 25% of Bayer Crop Science’s regional revenue, with 2024 estimated revenues ~USD 420 million from the brand (here’s the quick math: regional Crop Science revenue ~USD 1.68 billion).
Hybrid rice is a mature, low-capex market for Bayer, so Arize delivers steady gross margins near 38% and strong operating cash flow, funding R&D in digital ag and gene-editing programs.
Consumer Health Dermatology Brands
Bayer’s dermatology category, led by Bepanthen (wound care) and Canesten (antifungal), grew 7% in 2025 within a mature self-care market, driven by stable demand and premium pricing.
These brands hold high consumer trust and top market shares in Europe and Latin America, need maintenance-level investment, and deliver consistent, high-margin cash flows that stabilize Consumer Health results.
The cash generated funds Bayer’s digital transformation and R&D in other consumer segments; here’s the quick math: steady margins converting to predictable free cash flow for reinvestment.
- 7% sales growth in 2025
- High market share in core markets
- Maintenance capex only
- Funds digital/innovation spend
Radiology Contrast Media
Bayer’s Radiology Contrast Media unit, anchored by iodinated Ultravist and gadolinium-based Gadovist, stayed a cash cow in 2025 with ~4% volume growth and ~€1.1bn revenue, reflecting entrenched use in clinical imaging worldwide.
The unit delivered ~25–30% operating margin, low volatility, and predictable free cash flow that funds R&D across Bayer’s life‑science portfolio while consistently hitting internal targets.
- 2025 volume +4%
- Revenue ~€1.1bn
- Op margin 25–30%
- Stable cash flow, low volatility
Bayer’s 2024–25 cash cows: Xarelto, Mirena, Arize, Derm & Radiology fund R&D & debt
Xarelto, Mirena family, Arize hybrid rice, dermatology brands (Bepanthen/Canesten), and Radiology Contrast (Ultravist/Gadovist) are Bayer cash cows in 2024–25, generating recurring high-margin cash (Xarelto ~€3.4bn 2024; Mirena cluster ~€2.6bn 2025; Arize ~USD420m 2024; Radiology ~€1.1bn 2025) that covers maintenance capex and funds R&D and debt (net debt €18.9bn end‑2024).
| Brand/unit | 2024–25 sales | margin/notes |
|---|---|---|
| Xarelto | €3.4bn (2024) | High cash conv.; patent headwinds |
| Mirena family | €2.6bn (2025) | ~80% gross margin |
| Arize | USD420m (2024) | ~38% gross margin |
| Dermatology | — (2025 +7%) | Stable, premium pricing |
| Radiology Contrast | €1.1bn (2025) | Op margin 25–30% |
What You’re Viewing Is Included
Bayer BCG Matrix
The file you're previewing on this page is the final BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, ready-to-use strategic report built for clarity and professional presentation.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Unlock Strategic Clarity
Bayer’s BCG Matrix preview highlights how its diverse portfolio—pharmaceuticals, crop science, and consumer health—align across Stars, Cash Cows, Question Marks, and Dogs, revealing where growth potential and cash generation intersect with strategic risk. This snapshot shows which divisions drive market share and which may need divestment or reinvention. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Nubeqa Prostate Cancer Treatment
Nubeqa (darolutamide) reached blockbuster status with global sales above 1.5 billion euros by end-2025, growing >75% year-on-year and driving Pharmaceuticals segment revenue growth.
It’s rapidly gaining share as a leading androgen receptor inhibitor for metastatic hormone-sensitive prostate cancer and is a primary growth engine for Bayer.
A third regulatory approval in China is expected in 2026; Bayer is investing heavily in promotion to cement Nubeqa as a standard of care.
Kerendia for Chronic Kidney Disease
Kerendia for Chronic Kidney Disease is a Stars asset: sales surged nearly 87% in 2025 to about EUR 1.1 billion, driven by clear impact in type 2 diabetes patients with kidney disease.
The product is expanding via new indications, including 2025 priority reviews for heart failure, widening addressable market to ~45 million high-risk patients globally.
By end-2025 Kerendia plus Nubeqa formed Bayer’s pharma recovery backbone, contributing roughly EUR 2.3 billion combined sales; continued investment is needed to fend off renal and CV competitors.
Dekalb Hybrid Corn Portfolio
Dekalb Hybrid Corn is a Star in Bayer’s BCG matrix, holding a dominant 28% market share in India as of Q4 2025 and delivering double-digit revenue growth with ~22% ROI.
Bayer invested heavily in FY 2024–25 to expand global seed processing capacity, raising capex by about €300 million to meet rising demand for high-yield hybrids.
Projected to become a major cash generator for Crop Science, Dekalb’s high growth and strong margins support scaling R&D and global commercialization through 2026.
Eylea 8mg High-Dose
Eylea 8mg High-Dose has defended Bayer’s ophthalmology share by cutting dosing frequency, helping patient retention and adherence.
It showed mid-single-digit global sales growth in 2025, cushioning Bayer from biosimilar pressure on the 2mg dose.
Leading in the growing AMD and diabetic retinopathy markets, it stays a high-value Star backed by strategic marketing and robust clinical data.
- 2025 growth: ~5–7% global sales rise
- Fewer injections: extends dosing to Q12 weeks
- Offsets 2mg biosimilars
- High margin specialty product
Elinzanetant Menopause Management
Elinzanetant Menopause Management launched in late 2025 in the USA and Europe as a first-in-class non-hormonal therapy for vasomotor symptoms, entering a high-growth menopause market forecasted at ~6–8 billion euros by 2028; analysts project peak sales for Elinzanetant to exceed 1 billion euros.
As a first-to-market innovative product, it needs heavy Bayer support for market access and physician education—estimated launch investment €200–€350M—and, if current uptake holds, is on track to become the Women’s Healthcare segment’s primary revenue driver by 2027.
- Launch: late 2025 (US, EU)
- Type: non-hormonal, first-in-class
- Market size: ~€6–8B by 2028
- Peak sales: >€1B (analyst consensus)
- Estimated launch spend: €200–€350M
- Key year: primary driver by 2027
Bayer’s Blockbusters Surge: Nubeqa €1.5B, Kerendia €1.1B, Elinzanetant >€1B
Bayer Stars: Nubeqa €1.5B (2025), +75% YoY; Kerendia €1.1B, +87% (2025); Dekalb corn 28% India share, ~22% ROI; Eylea 8mg +5–7% (2025); Elinzanetant launch late‑2025, peak >€1B.
| Product | 2025 sales/metric | Growth/notes |
|---|---|---|
| Nubeqa | €1.5B | +75% YoY |
| Kerendia | €1.1B | +87% YoY |
| Dekalb | 28% India | ~22% ROI |
| Eylea 8mg | mid‑single % | Q12 dosing |
| Elinzanetant | launch 2025 | peak >€1B |
What is included in the product
Detailed Word Document
In-depth BCG review of Bayer’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page Bayer BCG Matrix placing each business unit in a quadrant for swift portfolio decisions
Cash Cows
Xarelto Anticoagulant Portfolio
Despite patent expirations and a 31% sales drop in Q1 2025, Xarelto (rivaroxaban) remains a major cash generator for Bayer, still delivering estimated annual net sales around €3.4 billion in 2024 and funding operations into 2025.
It holds a leading share in the mature anticoagulation market, requires minimal new capex, and its high cash conversion funds R&D for new launches and supports debt service—Bayer reported net debt of €18.9 billion at end-2024.
As the quintessential Cash Cow in Bayer’s BCG matrix, Xarelto provides the liquidity backbone for the company’s turnaround strategy while management milks remaining revenues to preserve margin and free cash flow.
Mirena Contraceptive Family
The Mirena contraceptive family, including Kyleena and Jaydess, stays the market leader in the mature long-acting reversible contraceptive (LARC) segment; in 2025 combined sales grew over 20% year-on-year to roughly €2.6 billion, driven by strong brand loyalty and high gross margins near 80%.
Arize Hybrid Rice
Arize Hybrid Rice holds a 32% share of the organized hybrid rice market in Asia and contributes about 25% of Bayer Crop Science’s regional revenue, with 2024 estimated revenues ~USD 420 million from the brand (here’s the quick math: regional Crop Science revenue ~USD 1.68 billion).
Hybrid rice is a mature, low-capex market for Bayer, so Arize delivers steady gross margins near 38% and strong operating cash flow, funding R&D in digital ag and gene-editing programs.
Consumer Health Dermatology Brands
Bayer’s dermatology category, led by Bepanthen (wound care) and Canesten (antifungal), grew 7% in 2025 within a mature self-care market, driven by stable demand and premium pricing.
These brands hold high consumer trust and top market shares in Europe and Latin America, need maintenance-level investment, and deliver consistent, high-margin cash flows that stabilize Consumer Health results.
The cash generated funds Bayer’s digital transformation and R&D in other consumer segments; here’s the quick math: steady margins converting to predictable free cash flow for reinvestment.
- 7% sales growth in 2025
- High market share in core markets
- Maintenance capex only
- Funds digital/innovation spend
Radiology Contrast Media
Bayer’s Radiology Contrast Media unit, anchored by iodinated Ultravist and gadolinium-based Gadovist, stayed a cash cow in 2025 with ~4% volume growth and ~€1.1bn revenue, reflecting entrenched use in clinical imaging worldwide.
The unit delivered ~25–30% operating margin, low volatility, and predictable free cash flow that funds R&D across Bayer’s life‑science portfolio while consistently hitting internal targets.
- 2025 volume +4%
- Revenue ~€1.1bn
- Op margin 25–30%
- Stable cash flow, low volatility
Bayer’s 2024–25 cash cows: Xarelto, Mirena, Arize, Derm & Radiology fund R&D & debt
Xarelto, Mirena family, Arize hybrid rice, dermatology brands (Bepanthen/Canesten), and Radiology Contrast (Ultravist/Gadovist) are Bayer cash cows in 2024–25, generating recurring high-margin cash (Xarelto ~€3.4bn 2024; Mirena cluster ~€2.6bn 2025; Arize ~USD420m 2024; Radiology ~€1.1bn 2025) that covers maintenance capex and funds R&D and debt (net debt €18.9bn end‑2024).
| Brand/unit | 2024–25 sales | margin/notes |
|---|---|---|
| Xarelto | €3.4bn (2024) | High cash conv.; patent headwinds |
| Mirena family | €2.6bn (2025) | ~80% gross margin |
| Arize | USD420m (2024) | ~38% gross margin |
| Dermatology | — (2025 +7%) | Stable, premium pricing |
| Radiology Contrast | €1.1bn (2025) | Op margin 25–30% |
What You’re Viewing Is Included
Bayer BCG Matrix
The file you're previewing on this page is the final BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, ready-to-use strategic report built for clarity and professional presentation.
